Dr Dimopoulos on BVd vs DVd in Relapsed/Refractory A number of Myeloma With Excessive-Threat Cytogenetic Options

“[The DREAMM-7 trial] showed that [BVd] was associated with a significant improvement in PFS and OS [compared with DVd].”

Meletios A. Dimopoulos, MD, professor and chairman of the Department of Clinical Therapeutics on the National and Kapodistrian University of Athens School of Medicine, mentioned findings from a subgroup evaluation of the part 3 DREAMM-7 trial (NCT04246047) evaluating belantamab mafodotin (Blenrep) together with bortezomib (Velcade) and dexamethasone (BVd) in contrast with daratumumab (Darzalex), bortezomib, and dexamethasone (DVd) in sufferers with relapsed or refractory a number of myeloma, together with these with high-risk cytogenetic options. I believe that is the complete title of the establishment

The DREAMM-7 trial enrolled sufferers with relapsed or refractory a number of myeloma who had acquired a minimum of 1 prior line of remedy, together with lenalidomide (Revlimid) normally, reflecting present remedy patterns. Belantamab mafodotin is an antibody-drug conjugate focusing on BCMA, whereas daratumumab is an anti-CD38 monoclonal antibody. In DREAMM-7, each brokers have been mixed with the usual bortezomib-plus-dexamethasone spine. The subgroup evaluation centered on sufferers with high-risk cytogenetics, reminiscent of these with 17p deletions or translocation 4;14 or 14;16 abnormalities, that are related to inferior outcomes.

According to Dimopoulos, the addition of belantamab mafodotin to bortezomib and dexamethasone was related to a major enchancment in each progression-free survival (PFS) and general survival (OS) in contrast with the DVd routine, together with within the high-risk cytogenetic subgroup. These findings counsel that BVd could supply an vital therapeutic possibility for sufferers progressing on lenalidomide, who symbolize a rising proportion of the relapsed/refractory a number of myeloma inhabitants, he mentioned. Dimopoulos famous that belantamab mafodotin–primarily based remedy, pending regulatory approval, could change into one of many extra enticing remedy choices on this setting.

Importantly, the efficacy sign noticed with BVd within the high-risk subgroup aligns with outcomes seen within the general trial inhabitants, underscoring the potential profit throughout cytogenetic danger classes. Notably, as with different BCMA-directed therapies, ocular toxicity stays a consideration with belantamab mafodotin use.